Mucosal immunity in mice immunized with HIV-1 peptide conjugated to Brucella abortus.
We have previously shown that a V3-loop peptide from HIV-1 envelope conjugated to heat-inactivated Brucella abortus (Ba) (V3-Ba) is capable of inducing antibodies that neutralize HIV-1 and cytotoxic T cells (CTL) that kill HIV-1-infected targets, even in mice that lack CD4(+) T cells. In this paper we show that intranasal (i.n.) immunization elicits neutralizing antibodies and IFNgamma-secreting T cells at mucosal surfaces. This approach may protect individuals from HIV-1 infection and reduce transmission from infected individuals to their sexual partners and offspring.
Golding
Basil
B
Laboratory of Plasma Derivatives, Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Woodmont, Rockville Pike, Rockville, MD 20852, USA. golding@cber.fda.gov
Eller
Nancy
N
Levy
Lily
L
Beining
Paul
P
Inman
John
J
Matthews
Natasha
N
Scott
Dorothy E
DE
Golding
Hana
H
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D002003:Brucella abortus / Q000276:immunology*; D005260:Female; D015483:HIV Antibodies / Q000097:blood; D015497:HIV-1 / Q000276:immunology*; D018928:Immunity, Mucosal; D007114:Immunization; D007371:Interferon-gamma / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D018074:Vaccines, Conjugate / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*
D016915:AIDS Vaccines; D015483:HIV Antibodies; D018074:Vaccines, Conjugate; D014759:Viral Envelope Proteins; D007371:Interferon-gamma